Exelixis
EXEL
#1694
Rank
โ‚น1.072 T
Marketcap
โ‚น3,985
Share price
-0.02%
Change (1 day)
30.57%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of September 2025 : โ‚น253.65 Billion

According to Exelixis's latest financial reports the company's total assets are โ‚น253.65 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2025)

Total assets by year

Year Total assets Change
2024-12-31โ‚น252.87 B3.24%
2023-12-31โ‚น244.94 B-3.63%
2022-12-31โ‚น254.16 B30.52%
2021-12-31โ‚น194.72 B24.58%
2020-12-31โ‚น156.31 B16.24%
2019-12-31โ‚น134.46 B35.21%
2018-12-31โ‚น99.44 B137.68%
2017-12-31โ‚น41.84 B3.35%
2016-12-31โ‚น40.48 B83.3%
2015-12-31โ‚น22.08 B7.8%
2014-12-31โ‚น20.48 B-34.11%
2013-12-31โ‚น31.09 B-21.25%
2012-12-31โ‚น39.48 B89.79%
2011-12-31โ‚น20.80 B28.68%
2010-12-31โ‚น16.16 B1.46%
2009-12-31โ‚น15.93 B-17.46%
2008-12-31โ‚น19.30 B19.35%
2007-12-31โ‚น16.17 B-7.65%
2006-12-31โ‚น17.51 B16.97%
2005-12-31โ‚น14.97 B18.66%
2004-12-31โ‚น12.61 B-22.55%
2003-12-31โ‚น16.29 B0.17%
2002-12-31โ‚น16.26 B-2.77%
2001-12-31โ‚น16.72 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
GlaxoSmithKline
GSK
โ‚น7.407 T 2,820.45%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚น13.684 T 5,294.77%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น11.637 T 4,488.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น8.704 T 3,331.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น8.097 T 3,092.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚น17.321 T 6,728.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น18.751 T 7,292.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
โ‚น2.48 B-99.02%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
โ‚น9.09 B-96.41%๐Ÿ‡บ๐Ÿ‡ธ USA